News

Merck Stays Confident On M&A Despite Market Uncertainty: Analyst
Merck projects $200 million in tariff costs, boosts U.S. manufacturing plans, and continues M&A efforts amid external pressures and shifting market dynamics.
STAT7h
Akeso wins Chinese approval for cancer drug positioned to rival Merck’s Keytruda
Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data ...
Merck Faces Lawsuit to Block Launch of Easier-to-Use Keytruda
A biotech company is suing to block Merck & Co. from launching an easier-to-use version of its blockbuster cancer treatment ...
pharmaphorum15h
Merck puts a price on its SpringWorks takeover bid
So far, SpringWorks – which was spun out of Pfizer in 2017 and has recently received FDA approval for a second therapy for a ...
Halozyme sues Merck; FDA blames cuts for Vanda delay
Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...
Merck Posts Higher Profit, Puts Tariffs Cost at $200 Million
For 2025, Merck said it still expects sales of $64.1 billion to $65.6 billion, but it lowered its adjusted earnings per share ...
Merck lowers profit outlook, partly due to $200 million expected tariff hit
Merck said the expected tariff charge primarily reflects levies between the U.S. and China, but does not account for Trump’s planned pharmaceutical tariffs.
Merck price target lowered to $82 from $89 at BMO Capital
BMO Capital analyst Evan Seigerman lowered the firm’s price target on Merck (MRK) to $82 from $89 and keeps a Market Perform rating on the ...